Nanogam (Human Normal Immunoglobulin)

Human Normal Immunoglobulin in Nanogam provides a broad spectrum of IgG antibodies that bind to pathogens, toxins and immune complexes. This neutralisation enhances opsonisation and phagocytosis, while interaction with Fc receptors delivers inhibitory signals that dampen auto‑reactive immune responses, thereby restoring immune balance.

The dose of Nanogam is individualized by the prescribing clinician based on factors such as patient body weight, baseline serum IgG levels, the severity of the immunodeficiency, and the specific clinical indication. No fixed regimen is provided; the prescriber calculates the appropriate infusion volume and rate.

Safety data for Nanogam in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Use is permitted only when the potential therapeutic benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician.

To order Nanogam, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Nanogam is a pooled human IgG preparation meeting EU standards, similar in composition to other intravenous immunoglobulin (IVIG) products. Differences among IVIGs may include manufacturing processes, stabilisers, and concentration, which can affect infusion tolerability and volume. Clinicians choose a product based on patient response, safety profile and logistical considerations.

Nanogam should be stored refrigerated at 2 °C to 8 °C. It must be kept in its original container, protected from light, and must never be frozen or shaken. Maintaining the cold chain is essential to preserve antibody integrity and efficacy.

Nanogam is given as an intravenous infusion. The infusion is started at a slow rate, typically 0.5 mL/kg/hour, and may be increased as tolerated. Administration is performed in a clinical setting where vital signs can be monitored for any infusion‑related reactions.

The most serious adverse events associated with Nanogam include anaphylaxis, aseptic meningitis, thromboembolic complications, and renal dysfunction. Patients should be observed closely during and after infusion, and any signs of severe allergic reaction, neurological symptoms, sudden pain, or changes in urine output require immediate medical evaluation.

Nanogam is contraindicated in individuals with a known severe IgA deficiency who have anti‑IgA antibodies, and in patients who have experienced a serious hypersensitivity reaction to immunoglobulin products. Caution is also advised for patients with uncontrolled renal disease or active thrombotic disorders.